Pharmaceuticals

Samsung Biologics listed among top most sustainable companies in Dow Jones Sustainability World Index

* Acknowledged for strong environmental, social, and governance (ESG) performance and continued commitment to sustainability through net-zero initiatives and responsible value chain management INCHEON, South Korea, Dec. 16, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contr...

2024-12-17 07:51 3079

Menarini Group announces Positive Topline Data from Pivotal Phase 3 BROADWAY & TANDEM Clinical Trials Evaluating Obicetrapib and the Fixed-Dose Combination Obicetrapib with Ezetimibe 10 mg

– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical significance (p<0.0001) – Approximately 50% of patients in BROADWAY (Obicetrapib monotherapy) and  over 70% of patients in TANDEM (Fixed Do...

2024-12-16 22:08 3523

Nona Biosciences Announces Discovery Collaboration with Candid Therapeutics for Next-Generation T-Cell Engagers

CAMBRIDGE, Mass., Dec. 16, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM ), today announced a research collaboration and license agreement to discover next-generation T-cell engagers ("TCEs") with Candid Therapeutics, ...

2024-12-16 20:03 1891

HiRO Forges Strategic Partnership with CHA University Bundang Medical Center in South Korea

SEOUL, South Korea, Dec. 16, 2024 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a boutique globalclinical research organization (CRO) providing cross-border clinical trial solutions, proudly announces the signing of a Memorandum of Understanding (MOU) with CHA University Bundan...

2024-12-16 10:30 5168

Innovent and Lilly Expand Collaboration Through Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China

SAN FRANCISCO and SUZHOU, China, Dec. 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2024-12-16 07:55 4829

Bushu Pharma Applauded by Frost & Sullivan for Offering Customer Value in APAC CDMO Industry Through Consistent Quality Assurance, On-time Delivery, Sustainability, and Competitive Costs

Bushu Pharma's ongoing investments and efforts offer customers state-of-the-art capabilities, increased capacity, and innovative solutions, providing top-tier pharmaceutical manufacturing and supply chain management services. SAN ANTONIO, Dec. 15, 2024 /PRNewswire/ -- Frost & Sullivan researched ...

2024-12-15 13:30 2682

Alphamab Oncology Presented the Phase II Clinical Data of KN046 in Combination with Axitinib for the Treatment of Advanced NSCLC at ESMO IO Congress 2024

SUZHOU, China, Dec. 13, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from a phase II clinical study on PD-L1/CTLA-4 bispecific antibody KN046 in combination with axitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC...

2024-12-13 10:35 3728

Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS

PRINCETON, N.J. and SUZHOU, China, Dec. 12, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, ann...

2024-12-13 08:00 2749

Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS

PRINCETON, N.J. and SUZHOU, China, Dec. 13, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, ann...

2024-12-13 08:00 3633

CureGene Received Clinical Trial Approval in China for CG-0255 for Injection - A Novel Antiplatelet Therapy

SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular and antiviral disease, proudly announces the approval of its Clinical Trial Application by theChina's...

2024-12-12 21:00 2706

Porton Pharma Solutions and Aojin Life Sciences Announce Strategic Collaboration to Advance XDC Conjugate Drugs for Dual IND Filings in China and the U.S.

CHONGQING, China, Dec. 12, 2024 /PRNewswire/ -- Recently, Porton Pharma Solutions Ltd. ("Porton") announced a strategic partnership with Aojin Life Sciences (Yixing) Co., Ltd. ("Aojin Life Sciences"). Porton will provide comprehensi...

2024-12-12 21:00 2954

SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate

* SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials inAustralia in February 2025, with interim results expected by 2026. * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI. * SK bioscience will respond to...

2024-12-12 21:00 3895

Xinhua Silk Road: Pien Tze Huang boosts TCM globalization

BEIJING, Dec. 12, 2024 /PRNewswire/ -- Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd., aFujian-based traditional Chinese medicine (TCM) company, has been striving to expand its overseas markets, enhancing the influence of TCM in regions such asSoutheast Asia and Europe. Committed to deepening...

2024-12-12 20:43 3115

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

* ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast cancer withESR1 mutations, aiming to delay disease progression. * The study was presented by the Menarini Group and MEDSIR at the San Ant...

2024-12-12 18:07 3809

KIND Presents Preclinical Results of AND017 in Animal Models of Sickle Cell Disease (SCD), Myelodysplastic Syndromes (MDS), and β-Thalassemia at the 66th American Society of Hematology Meeting and Exposition and Announces FDA Authorization of Investigational New Drug (IND) Application for AND017 for Clinical Trial in Sickle Cell Disease (SCD)

SAN FRANCISCO, Dec. 12, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that preclinical...

2024-12-12 16:25 2229

Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients

SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first prescription of VELSIP...

2024-12-12 11:48 3251

Nature Biotechnology | Generative Chemistry Enables Insilico to Develop Gut-Restricted PHD Inhibitors Promising for Intestinal Mucosal Barrier Repair and Immunomodulation

* The study presents the journey of designing and optimizing novel gut-restricted PHD inhibitors using the comprehensive generative chemistry engine Chemistry42. * From initiation to preclinical candidate nomination, the program spanned only 12 months, during which approximately 115 molecules...

2024-12-11 22:25 2862

Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer

Sunvozertinib, as a single agent, demonstrated promising antitumor activity and favorable safety profile in heavily pretreated patients with EGFR-mutated NSCLC who had developed resistance to EGFR TKI treatment SHANGHAI, Dec. 11, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical compa...

2024-12-11 18:05 3090

Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion

HONG KONG, Dec. 11, 2024 /PRNewswire/ -- Recently, Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch inBoston ,USA. As a global leader in drug research, development and manufacturing services, this milestone marks a significant step forward in the ...

2024-12-11 14:44 4672

Call for Application for 2025 Tsinghua Amgen Scholars Program

BEIJING, Dec. 11, 2024 /PRNewswire/ -- The Amgen Scholars Program (ASP) is an international program funded by the Amgen Foundation with the direction of Harvard University, aiming to increase research opportunities for students committed to pursuing careers in the field of biomedical science. Thro...

2024-12-11 14:33 5328
1 ... 108109110111112113114 ... 345

Week's Top Stories